The increased risk of thyroid cancer following childhood exposure to external radiation or internal radiation due to iodine-131 (^131^I) from the Chernobyl nuclear power plant accident on 26 April 1986 is now well established ([@bib38]; [@bib2]). The largest increase in thyroid cancer was observed among subjects 18 years or younger at the time of the accident. Children received higher thyroid radiation doses on average due to their smaller thyroid mass and higher rates of milk consumption, the main route of ^131^I exposure, and their increased sensitivity to the carcinogenic effects of thyroid irradiation compared with adults ([@bib37], [@bib38]). Papillary thyroid carcinoma (PTC) is the main histological type of post-Chernobyl thyroid cancer ([@bib39]; [@bib22]; [@bib9]; [@bib2]).

A number of histopathological and molecular studies have examined post-Chernobyl thyroid cancer ([@bib4], [@bib5]; [@bib15]; [@bib22]; [@bib1]; [@bib17], [@bib18]; [@bib28], [@bib29]; [@bib42]). However, data on how the histopathological characteristics of PTCs are related to radiation dose and genetic alterations are limited. A recent Belarusian-American thyroid screening study (BelAm) reported that higher ^131^I doses were associated with a higher frequency of solid or diffuse-sclerosing variants of PTC and histopathological features of cancer aggressiveness, such as lymph vessel invasion, intrathyroidal spreading, and multifocality ([@bib42]). We previously reported the results of a detailed histopathological analysis, without considering individual ^131^I doses, of 56 thyroid carcinomas diagnosed in a Ukrainian-American cohort (UkrAm) in the first cycle of thyroid screening examinations conducted during 1998--2000 ([@bib5]; [@bib6]). The BelAm and UkrAm studies had similar designs, methods of screening, and estimations of ^131^I dose ([@bib31]; [@bib35]). Since 2000, 3 additional cycles of screening examinations have been completed in this UkrAm cohort, and 65 new cases of thyroid cancer have been identified. Analysis of radiation risk demonstrated a significant ^131^I-related excess persisting two decades following the accident ([@bib7]). The objectives of the current analysis were three-fold: (1) to evaluate associations between ^131^I dose and histopathological characteristics of PTCs in the UkrAm cohort; (2) to evaluate changes in these characteristics over time from prescreening through the fourth cycle of screening; and (3) to evaluate the associations between common somatic alterations and histopathological characteristics in a subset of carcinomas for which somatic mutation profiling has been performed ([@bib17], [@bib18]).

Materials and methods
=====================

Study population and cases
--------------------------

The study protocol was approved by the Institutional Review Boards of the National Cancer Institute (NCI), Bethesda, MD, USA, and Institute of Endocrinology and Metabolism (IEM), Kyiv, Ukraine. All participants or their guardians (for minors) provided written informed consent. The methods of cohort recruitment and follow-up for both the UkrAm and BelAm cohorts have been described previously ([@bib31]; [@bib35], [@bib34]). In brief, the UkrAm cohort includes 13 243 individuals \<18 years at the time of the accident who resided in 10 highly contaminated raions (counties) of three northern oblasts (states) of Ukraine (Kyiv, Zhytomyr, and Chernihiv) and underwent direct thyroid radioactivity measurements in May--June 1986. Four consecutive standardised thyroid screenings were implemented in the years 1998--2000, 2001--2003, 2003--2005, and 2005--2007, respectively.

As a result of the 4 screening examinations, 904 individuals were referred for fine needle aspiration biopsy (FNAB), and 849 (94%) complied between 1998 and 2008. All individuals who had a large, multinodular goiter or whose FNAB report indicated one of the following: 'cancer\', 'suspicious for cancer\', 'follicular neoplasm\', or 'suspicious for follicular neoplasm\' ([@bib6]) were referred for thyroid surgery (*n*=196). By 31 December 2008, 167 individuals (85%) had undergone surgery. In addition, 49 individuals underwent surgery before the first screening started in October 1998, and histological samples were available for 20 of these individuals. Thus, the total number of operated cohort members with available histopathological samples was 187. Postoperative study of paraffin sections or intraoperative evaluation of frozen sections (for cases 'suspicious for cancer\') was performed at the Laboratory of Morphology of Endocrine System of the IEM ([@bib5]). All histopathological diagnoses established according to the World Health Organisation (WHO) classification ([@bib8]) were additionally reviewed by the International Pathology Panel of the Chernobyl Tissue Bank (CTB) ([@bib40]). The PTCs were further classified according to the dominant histological pattern into three groups: classic papillary, follicular, or solid (when approximately \>50% of the slide\'s surface had the corresponding structure). In addition, PTCs were subdivided into main histological variants according to the WHO classification: classic papillary, follicular, solid, diffuse-sclerosing, Warthin-like (when \>80% of the slide\'s surface had the corresponding structure), or mixed (when the tumour was composed of a combination of at least two patterns in nearly equal proportions). Tumour stage was characterised according to the 7th edition of the TNM classification system ([@bib30]).

For 65 PTCs diagnosed during the first through fourth screening cycles, RNA and DNA aliquots extracted from fresh frozen tissue were previously used in focused genetic profiling ([@bib17], [@bib18]). In the present study, we analysed the associations between common somatic alterations and histopathological characteristics.

Dosimetry
---------

Estimated thyroid doses due to ^131^I intake based on the interview data obtained at the first screening of the UkrAm cohort ([@bib19]) were subsequently revised and improved in a second round of interviews ([@bib20]). Doses were estimated based on (1) direct radioactivity measurements in the thyroid gland taken within 2 months of the accident; (2) ecological and biokinetic models used to assess the temporal variation of ^131^I radioactivity in the thyroid; and (3) information on individual behaviour and dietary habits obtained in personal interviews. The revised thyroid doses were improved based on (1) new estimates of daily ^131^I and ^137^Cs ground deposition densities in all places of residence ([@bib33]); (2) correction of the response of thyroid detectors used for direct thyroid measurements to the contribution of radiocaesiums (^134^Cs, ^136^Cs, ^137^Cs) incorporated in the human body; (3) the use of age-, sex-, and region-specific thyroid mass data derived from autopsy measurements and measurements of thyroid volume performed in the 1990s in Ukraine by the Sasakawa Memorial Health Foundation ([@bib21]); (4) modified dosimetry questionnaires to collect detailed information on personal behaviour, that is, relocation history; consumption of contaminated milk, dairy products and leafy vegetables; and administration of stable iodine.

Statistical analysis
--------------------

We assessed the trends in the demographic and histopathological characteristics of the PTCs over five time periods (from prescreening to fourth screening) as follows. For continuous variables (e.g., age and ^131^I dose), changes over time were evaluated using linear regression models. For categorical variables with multiple outcomes (e.g., dominant histological pattern and histological variant), changes over time were evaluated using polytomous logistic regression models. For binary outcomes (e.g., sex and the presence of capsule), polytomous regression was reduced to binary logistic regression. For both linear regression and logistic regression models, we conducted tests of univariate linear trends and tests of linear trends adjusted for age at surgery (i.e., measure of attained age), a major factor underlying the risk of thyroid cancer and its characteristics in unexposed populations.

To evaluate the associations between individual histopathological characteristics and ^131^I thyroid dose, we used logistic regression models. We estimated odds ratios (ORs) for each characteristic with four dose categories chosen to ensure a reasonable distribution of cases (⩽0.30, 0.31--1.00, 1.01--2.00, ⩾2.01 gray (Gy)) using ⩽0.30 Gy as the referent category. We evaluated continuous dose trends based on linear and linear-quadratic (on a log scale) dose--response models. We evaluated the linear-quadratic trend because our previous analyses of dose--response for chromosomal rearrangements suggested non-linearity ([@bib17]). All dose--response analyses were adjusted for age at surgery unless specified otherwise.

To evaluate the associations between histopathological characteristics and genetic alterations in the subset of cases, we used standard approaches and fitted logistic regression models to several binary outcomes ([@bib10]; [@bib12]). The outcomes of interest were defined as tumours with point mutations (in *BRAF, HRAS, KRAS*, or *NRAS* genes) *vs* no point mutations or chromosomal rearrangements (*RET/PTC1*, *RET/PTC3*, *PAX8/PPARγ*, or *ETV6-NTRK3*) *vs* no chromosomal rearrangements. The associations with histopathological characteristics were adjusted for sex, oblast of residence in 1986, and ^131^I dose (in addition to age at surgery) because these factors were significantly associated with both types of genetic alterations in previous analyses ([@bib17]). We also compared histopathological characteristics in cases with chromosomal rearrangements and point mutations directly using the heterogeneity test described by [@bib25].

Analyses were conducted using SAS version 9.3 software ([@bib27]). All tests were two-sided and likelihood ratio-based; *P*\<0.05 was considered as statistically significant. Analyses with very small numbers of outcomes (\<5 per cell) were conducted using exact logistic regression methods.

Results
=======

Thyroid carcinoma was identified in 121 (64.7%) of the 187 individuals who underwent surgery by the end of 2008 and for whom histopathological samples were available. In all, 11 thyroid carcinomas were removed before the first screening (i.e., prescreening), 45 following the first screening (cycle 1), 32 following the second screening (cycle 2), 17 following the third screening (cycle 3), and 16 following the fourth screening (cycle 4) ([Table 1](#tbl1){ref-type="table"}). Overall, PTC was identified in 115 of 121 cases (95.0%), follicular thyroid carcinoma (FTC) in 5 cases (4.1%), and medullary thyroid carcinoma (MTC) in 1 case (0.9%). One patient who underwent surgery before the first screening had both PTC and small MTC (with MTC described as concomitant thyroid cancer). No cases of poorly differentiated or anaplastic carcinoma were identified. All further analyses were limited to PTCs.

Changes in the characteristics of PTCs over time
------------------------------------------------

Most PTC cases were female, and the proportion of females did not significantly vary over time ([Table 1](#tbl1){ref-type="table"}). More than 60% of all PTC cases were children who were \<10 years old at the time of the Chernobyl accident. The youngest age at exposure was observed in the prescreening cases, and there was no significant trend in age at exposure over time (*P*=0.479). However, we observed a significant increase in age at surgery over time (*P*=0.002, [Table 1](#tbl1){ref-type="table"}). We also observed a significant decrease in ^131^I thyroid dose over time, although this trend did not persist after adjustment for age at surgery (*P*=0.124).

The size of PTC upon histopathology ranged from 1 to 50.0 mm; the average size (in the largest dimension) decreased significantly from 23.6 mm in prescreening cases to 8.4 mm in cycle 4 cases (*P*\<0.001), whereas the corresponding frequency of PTCs \>10.0 mm decreased from 100% to 33.3% (*P*\<0.001, [Table 2](#tbl2){ref-type="table"}). The decreasing trends in tumour size distribution remained highly significant after adjustment for age at surgery ([Table 2](#tbl2){ref-type="table"}).

Throughout the study, non-encapsulated PTCs were more common. Whereas the frequency of fully encapsulated PTCs was lowest among prescreening cases and highest among cycle 4 cases ([Table 2](#tbl2){ref-type="table"}), no significant time trend was observed (*P*=0.892). Similarly, we observed no significant trend in the proportion of PTCs classified according to dominant histological pattern or histological variant (*P*=0.686 and *P*=0.653, respectively, [Table 2](#tbl2){ref-type="table"}).

After controlling for age at surgery, there was evidence of a significant increase over time in the proportion of PTCs with intrathyroidal spreading (*P*=0.014, [Table 3](#tbl3){ref-type="table"}). Although the decreasing trend in extrathyroidal extension with time was not significant (*P*=0.351), trends for other invasive tumour properties were significant, that is, lymphatic/vascular invasion (*P*=0.005) and combined characteristics of tumour invasiveness (i.e., at least one of the following: extrathyroidal extension, lymphatic/vascular invasion, regional lymph-node and distant lung metastases *vs* none) (*P*=0.026, [Table 3](#tbl3){ref-type="table"}). Interestingly, no distant metastases (M1) were detected in either cycle 3 or 4 cases ([Table 3](#tbl3){ref-type="table"}). Signs of multifocal growth were noted in cycle 1, 2, and 4 cases, although no evidence of a significant trend was observed (*P*=0.601). In most multifocal PTCs, the structure and degree of encapsulation of other tumour foci differed from the main lesion (not shown). The increase in the proportion of PTCs with concomitant benign thyroid pathology over time was not significant after adjustment for age (*P*=0.295, [Table 3](#tbl3){ref-type="table"}). In each cycle of screening, there were PTCs associated with the presence of follicular adenoma, hyperplastic nodule(s), or chronic thyroiditis, and no particular pattern was observed for the specific presence of any one of these pathologies (not shown).

Associations between histopathological characteristics of PTCs and ^131^I dose
------------------------------------------------------------------------------

None of the individual histopathological characteristics of PTCs, that is, intrathyroidal spreading, extrathyroidal extension, and lymphatic/vascular invasion or metastases, was significantly associated with ^131^I dose either in categorical or in continuous analyses of the dose--response ([Supplementary Table 1](#sup1){ref-type="supplementary-material"} and [Table 4](#tbl4){ref-type="table"}). However, for lymphatic/vascular invasion and for the combined characteristics of tumour invasiveness, the ORs with ^131^I dose categories (higher than 0.30 Gy) were consistently \>1 and, for the combined characteristics of tumour invasiveness, there was a borderline significant linear-quadratic trend with dose (*P*=0.063) increasing at low-to-moderate doses and decreasing at high doses ([Table 4](#tbl4){ref-type="table"}).

Associations between the histopathological characteristics of PTCs and genetic alterations
------------------------------------------------------------------------------------------

[Supplementary Table 2](#sup1){ref-type="supplementary-material"} summarises the distribution of 65 PTCs with specific genetic alterations according to the selected histopathological characteristics. There was a high proportion of solid variant tumours among *RET/PTC3*-positive PTCs, whereas there was a high proportion of follicular variant tumours among *ETV6-NTRK3*-positive PTCs. In addition, both *RET/PTC3-* and *ETV6-NTRK3*-positive PTCs had a high proportion of tumours with lymphatic/vascular invasion. Both PTCs positive for *PAX8/PPARγ* rearrangement were of the follicular variant.

[Table 5](#tbl5){ref-type="table"} presents the ORs for PTCs grouped according to the presence or absence of point mutations (*BRAF* or *RAS*) or chromosomal rearrangements (*RET*/*PTC*, *PAX8/PPARγ*, or *ETV6*-*NTRK3*). The PTCs with chromosomal rearrangements tended to have increased ORs with invasive tumour properties ([Table 5](#tbl5){ref-type="table"}). In particular, the OR associated with lymphatic/vascular invasion was significantly elevated (OR=5.85; 95% CI: 1.43--31.75). In general, the patterns of ORs in relation to various histopathological characteristics of PTCs with chromosomal rearrangements were opposite those for PTCs with point mutations ([Table 5](#tbl5){ref-type="table"}). When compared directly, tumours with chromosomal rearrangements were significantly more likely to have intrathyroidal spreading (*P*=0.020) and lymphatic/vascular invasion (*P*=0.008) than tumours with point mutations ([Table 5](#tbl5){ref-type="table"}).

Discussion
==========

In a large thyroid screening cohort in Ukraine comprising individuals exposed to ^131^I from the Chernobyl accident during childhood or adolescence, PTC continues to be the main tumour type, regardless of the screening cycle. We observed strong, significant trends in decreasing tumour size and invasive properties of PTCs with each subsequent screening after adjustment for increasing age at surgery. Combining all PTCs diagnosed in the cohort by the end of 2008, we identified a borderline significant non-linear ^131^I dose response for the combined characteristics of tumour invasiveness, defined as the presence of extrathyroidal extension, lymphatic/vascular invasion, or metastases. In a subset of tumours for which somatic mutation profiling was performed, irrespective of ^131^I dose, we observed a significantly increased OR with the presence of lymphatic/vascular invasion for cases with common chromosomal rearrangements relative to cases without chromosomal rearrangements or to cases with *BRAF*/*RAS* point mutations.

The differences in the histopathological or invasive properties of thyroid carcinomas in irradiated populations and unirradiated populations and the relationships between these properties and radiation dose have not been clearly elucidated. Several studies of post-Chernobyl thyroid cancers have implied that radiation-related cases tend to be more aggressive and/or advanced at presentation, particularly in paediatric cases ([@bib4]; [@bib36]), although others have demonstrated that the invasive properties of post-Chernobyl PTCs are related to young age at onset ([@bib36]). Specifically, a study of 168 PTCs (\<15 years of age at diagnosis) in Ukraine detected a significant increase in the proportion of aggressive solid-follicular variant tumours with higher average settlement-specific ^131^I doses ([@bib4]). Another study of 125 post-Chernobyl PTC cases diagnosed in Ukraine (15--23 years of age at diagnosis) and a comparable number of age-matched 'unexposed\' cases born after the accident reported that the odds of extrathyroidal invasion were approximately three times higher in cases 'exposed\' to ^131^I than in 'unexposed\' cases ([@bib3]). A recent study of 158 PTCs diagnosed in the thyroid screening cohort in Belarus (BelAm) identified a significant linear association between several characteristics of tumour invasiveness (i.e., lymphatic invasion, intrathyroidal spreading, and multifocality) and individual, measurement-based ^131^I thyroid doses in analyses adjusted for age at surgery ([@bib42]). In the current study, which was designed, conducted, and analysed according to similar methods ([@bib31]; [@bib35]), we observed a borderline significant linear-quadratic association for the combined characteristics of tumour invasiveness; this association seemed to be driven mainly by lymphatic/vascular invasion. In contrast to the BelAm study, no significant dose--response associations with other characteristics of tumour invasiveness were observed in the UkrAm study.

The apparent differences between the UkrAm and BelAm studies may be due to the smaller number of cases (115 *vs* 158) and consequently lower statistical power of the UkrAm study. In addition, the proportion of solid variant PTCs, which are associated with more aggressive tumour properties, was lower in the UkrAm study (10% *vs* 28%) despite the generally comparable distribution of sex, age, and ^131^I dose ([@bib42]). The reasons for this discrepancy are unclear but are likely to be important because the frequency of solid or diffuse-sclerosing variants of PTC (of which 92% were solid variant PTC) increased significantly with ^131^I dose in the BelAm study. The extent to which this relationship may have confounded the dose-related increase in aggressive PTC properties observed in the BelAm study remains to be determined. The differences in the dose--response shape, that is, linear in BelAm and nearly linear-quadratic in UkrAm, must be considered while taking into account the uncertainty of thyroid dose estimates. On average, uncertainties in ^131^I doses were lower in the UkrAm than in the BelAm study (mean GSD 1.55 *vs* 1.76) but should be formally incorporated into the analysis ([@bib20]; [@bib11]).

Despite differences in their findings, both the UkrAm and BelAm studies concluded that invasive PTC properties, particularly lymphatic/vascular invasion, may be related to ^131^I dose. This evidence must be considered in the context of repeated screenings of populations. As screenings in both studies were standardised and conducted irrespective of dose, confounding by screening intensity is unlikely. A dose--response for combined-characteristic of tumour invasiveness was suggested in the UkrAm study, although the proportion of small, less invasive PTCs increased with each screening. Although the BelAm study reported no analyses of invasive tumour characteristics according to individual screening cycles, comparison of prescreening, prevalent (first cycle), and incident (second and third cycles) PTCs revealed similar patterns ([@bib42]). There is no doubt that repeated thyroid examinations with sensitive ultrasound devices and FNAB contribute to the early detection of PTCs while they are small and localised.

There is accumulating evidence that the types of somatic mutations in PTC may indicate aetiology ([@bib23]). Certain chromosomal rearrangements, for example, *RET*/*PTC*, *ETV6-NTKR3*, and *EML4*-*ALK*, may be characteristic of radiation-related thyroid cancer, whereas point mutations in the *BRAF* or *RAS* genes may be characteristic of sporadic cancer ([@bib32]; [@bib14], [@bib13]; [@bib17], [@bib18]). Our previous findings in a subset of UkrAm cases support this idea ([@bib17], [@bib18]). We reported that the frequency of several chromosomal rearrangements as a group followed a linear-quadratic dose--response, whereas the frequency of the *BRAF*/*RAS* mutations was inversely and linearly associated with ^131^I dose ([@bib17]). Given that the association between dose and the combined characteristics of PTC invasiveness also followed a concave pattern, we evaluated the associations between somatic mutations and the invasive properties of PTCs.

Much evidence on this subject comes from non-irradiated patients in whom the presence of the *BRAF* V600E mutation has been associated with aggressive PTC histopathology and adverse clinical outcomes ([@bib16]; [@bib24]). By contrast, some studies of radiation-related post-Chernobyl PTCs have suggested that *RET*/*PTC* (particularly *RET*/*PTC3*) rearrangements occur frequently in morphologically aggressive solid variant tumours ([@bib26]; [@bib41]). In our study, five of eight *RET*/*PTC3-*positive tumours were of the solid variant, seven had evidence of extrathyroidal extension, and all eight had evidence of lymphatic/vascular invasion. In addition, we observed that PTCs with chromosomal rearrangements were significantly associated with lymphatic/vascular invasion compared with PTCs without chromosomal rearrangements or PTCs with *BRAF*/*RAS* point mutations after adjustment for age and ^131^I dose. Therefore, PTCs with chromosomal rearrangements may be more aggressive (i.e., lymphatic/vascular invasion), regardless of the received thyroid dose and age. Moreover, PTCs with common chromosomal rearrangements and *BRAF*/*RAS* point mutations may have both different aetiologies and distinct phenotypes.

Among the major strengths of our study are the availability of measurement-based individual ^131^I thyroid dose estimates, screening according to a standardised protocol and irrespective of dose, high rates of compliance with FNAB and thyroid surgery (94% and 85%, respectively), and histopathological diagnoses based on the review of diagnostic material by an international pathology panel. However, limitations include limited statistical power, availability of genetic data for only a subset of cases (57%), and a lack of clinical follow-up data.

In conclusion, our study corroborates and extends evidence that the aggressive properties of PTCs diagnosed in individuals exposed to ^131^I from the Chernobyl accident as children or adolescents may be associated with the radiation dose and the presence of chromosomal translocations. The observed dose--response and genotype--phenotype associations require confirmation in large-scale studies of radiation-related PTCs. Clinical studies should evaluate whether changes in invasive PTC properties due to irradiation and repeated screening may lead to changes in clinical outcomes.
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###### 
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###### General characteristics of 115 PTC cases[a](#t1-fn2){ref-type="fn"}

                             **Prescreening**   **Cycle 1**   **Cycle 2**   **Cycle 3**   **Cycle 4**             
  ------------------------- ------------------ ------------- ------------- ------------- ------------- --------- ----------------------------------
  Female                         7 (63.6)        29 (67.4)     15 (50.0)     11 (68.8)     9 (60.0)      0.712    
  Age at exposure, years        4.9 (5.1)        8.5 (4.8)     9.3 (4.8)     7.4 (5.4)     8.2 (3.9)     0.479    
  Age at surgery, years         14.0 (5.6)      23.2 (5.1)    26.5 (5.1)    26.7 (5.6)    29.0 (4.4)    \<0.001  0.002[c](#t1-fn4){ref-type="fn"}
  ^131^I thyroid dose, Gy       3.4 (3.8)        1.6 (2.3)     1.0 (2.2)     0.7 (1.0)     0.4 (0.6)    \<0.001  0.124[d](#t1-fn5){ref-type="fn"}
  Total                             11              43            30            16            15                  

Abbreviations: PTC=papillary thyroid carcinoma; s.d.=standard deviation.

Diagnosed in the Ukrainian-American cohort study of thyroid cancer and other thyroid diseases through 2008.

*P-*value of univariate trend.

*P*-value of trend adjusted for ^131^I thyroid dose.

*P*-value of trend adjusted for age at surgery.

###### Histopathological characteristics of 115 PTC cases[a](#t2-fn2){ref-type="fn"}

                              **Prescreening**   **Cycle 1**   **Cycle 2**   **Cycle 3**   **Cycle 4**                 
  -------------------------- ------------------ ------------- ------------- ------------- ------------- --------- ---------
  Tumour size, mm               23.6 (13.6)      16.9 (9.6)    11.7 (5.9)    10.9 (5.9)     8.4 (3.9)    \<0.001   \<0.001
   1--10                             0            10 (23.3)     12 (40.0)     8 (50.0)      10 (66.7)                  
   11--50                        11 (100.0)       33 (76.7)     18 (60.0)     8 (50.0)      5 (33.3)     \<0.001   \<0.001
  **Presence of capsule**                                                                                         
  No                             10 (90.9)        36 (83.7)     23 (76.7)     14 (87.5)     10 (66.7)                  
  Yes                             1 (9.1)         7 (16.3)      7 (23.3)      2 (12.5)      5 (33.3)      0.195     0.892
  **Dominant pattern**                                                                                            
  Papillary                       3 (27.3)        14 (32.6)     15 (50.0)     9 (56.3)      4 (26.7)                   
  Follicular                      3 (27.3)        22 (51.2)     10 (33.3)     5 (31.3)      8 (53.3)                   
  Solid                           5 (45.5)        7 (16.3)      5 (16.7)      2 (12.5)      3 (20.0)      0.548     0.686
  **Histological variant**                                                                                        
  Papillary                          0            8 (18.6)      8 (26.7)      2 (12.5)      2 (13.3)                   
  Follicular                      2 (18.2)        14 (32.6)     7 (23.3)      3 (18.8)      3 (20.0)                   
  Solid                           3 (27.3)        5 (11.6)      3 (10.0)          0          1 (6.7)                   
  Mixed                           4 (36.4)        16 (37.2)     12 (40.0)     10 (62.5)     9 (60.0)                   
  Diffuse-sclerosing              2 (18.2)            0             0             0             0                      
  Warthin-like                       0                0             0          1 (6.3)          0         0.132     0.653

Abbreviations: PTC=papillary thyroid carcinoma; s.d.=standard deviation.

Diagnosed in the Ukrainian-American cohort study of thyroid cancer and other thyroid diseases through 2008.

*P-*value of univariate trend.

*P*-value of trend adjusted for age at surgery.

###### Invasive properties and benign concomitant thyroid pathology of 115 PTC cases[a](#t3-fn2){ref-type="fn"}

                                                          **Prescreening**   **Cycle 1**   **Cycle 2**   **Cycle 3**   **Cycle 4**                
  ------------------------------------------------------ ------------------ ------------- ------------- ------------- ------------- --------- -------
  **Intrathyroidal spreading**                                                                                                                
  No                                                          3 (27.3)        12 (27.9)     7 (23.3)       1 (6.3)      2 (13.3)                  
  Yes                                                         8 (72.7)        31 (72.1)     23 (76.7)     15 (93.8)     13 (86.7)     0.105    0.014
  **Extrathyroidal extension**                                                                                                                
  No (T1 or T2)[d](#t3-fn5){ref-type="fn"}                    7 (63.6)        24 (55.8)     25 (83.3)     10 (62.5)     14 (93.3)                 
  Yes (T3)[d](#t3-fn5){ref-type="fn"}                         4 (36.4)        19 (44.2)     5 (16.7)      6 (37.5)       1 (6.7)      0.025    0.351
  **Lymphatic/vascular invasion**                                                                                                             
  No                                                             0            16 (37.2)     15 (50.0)     7 (43.8)      13 (86.7)                 
  Yes                                                        11 (100.0)       27 (62.8)     15 (50.0)     9 (56.3)      2 (13.3)     \<0.001   0.005
  **Lymph-node metastases**                                                                                                                   
  No (N0)[d](#t3-fn5){ref-type="fn"}                          4 (36.4)        28 (65.1)     24 (80.0)     12 (75.0)     13 (86.7)                 
  Yes (N1a or N1b)[d](#t3-fn5){ref-type="fn"}                 7 (63.6)        15 (34.9)     6 (20.0)      4 (25.0)      2 (13.3)      0.009    0.202
  **Distant lung metastases**                                                                                                                 
  No (M0)[d](#t3-fn5){ref-type="fn"}                         10 (90.9)        40 (93.0)     29 (96.7)    16 (100.0)    15 (100.0)                 
  Yes (M1)[d](#t3-fn5){ref-type="fn"}                         1 (9.1)          3 (7.0)       1 (3.3)          0             0         0.125    0.416
  **Combined invasiveness**[e](#t3-fn6){ref-type="fn"}                                                                                        
  None                                                           0            13 (30.2)     12 (40.0)     5 (3l.2)      12 (80.0)                 
  At least one                                               11 (100.0)       30 (69.8)     18 (60.0)     11 (68.8)     3 (20.0)     \<0.001   0.026
  **Multifocality**                                                                                                                           
  No                                                         11(100.0)        36 (83.7)     25 (83.3)    16 (100.0)     13 (86.7)                 
  Yes (*T*~m~)[d](#t3-fn5){ref-type="fn"}                        0            7 (16.3)      5 (16.7)          0         2 (13.3)      0.906    0.601
  **Benign concomitant thyroid pathology**                                                                                                    
  No                                                         11 (100.0)       31 (72.1)     19 (63.3)     10 (62.5)     8 (53.3)                  
  Yes                                                            0            12 (27.9)     11 (36.7)     6 (37.5)      7 (46.7)      0.021    0.296

Abbreviation: PTC=papillary thyroid carcinoma.

Diagnosed in the Ukrainian-American cohort study of thyroid cancer and other thyroid diseases through 2008.

*P-*value of univariate trend.

*P*-value of trend adjusted for age at surgery.

Grouping according to tumour-node-metastasis classification.

At least one of the following: extrathyroidal extension, lymphatic/vascular invasion, lymph-node metastases, or distant lung metastases.

###### Dose--response associations for invasive properties and benign concomitant thyroid pathology of 115 PTC cases[a](#t4-fn2){ref-type="fn"}

                                                                                       ^**131**^**I thyroid dose, Gy**                                                                       
  ----------------------------------------------------------------------------------- --------------------------------- ------------------- -------------------- ------------------- ------- -------
  **Intrathyroidal spreading**                                                                                                                                                               
  No                                                                                              12 (25.5)                  5 (17.9)             2 (14.3)            6 (23.1)                
  Yes                                                                                             35 (74.5)                  23 (82.1)           12 (85.7)            20 (72.9)               
  OR[d](#t4-fn5){ref-type="fn"} ~Yes\ *vs*\ No~ (95% CI)[e](#t4-fn6){ref-type="fn"}                 1.00                 1.36 (0.42--5.00)   1.76 (0.38--2.77)    0.91 (0.26--0.37)  0.387   0.680
  **Extrathyroidal extension**                                                                                                                                                               
  No (T1 or T2)[f](#t4-fn7){ref-type="fn"}                                                        36 (76.6)                  19 (67.9)            9 (64.3)            16 (61.5)               
  Yes (T3)[f](#t4-fn7){ref-type="fn"}                                                             11 (23.4)                  9 (32.1)             5 (35.7)            10 (38.5)               
  OR~Yes\ *vs*\ No~ (95% CI)                                                                        1.00                 0.99 (0.31--3.04)   1.18 (0.29--4.47)    1.03 (0.30--3.41)  0.422   0.198
  **Lymphatic/vascular invasion**                                                                                                                                                            
  No                                                                                              29 (61.7)                  10 (35.7)            3 (21.4)            9 (34.6)                
  Yes                                                                                             18 (38.3)                  18 (64.3)           11 (78.6)            17 (65.4)               
  OR~Yes\ *vs*\ No~ (95% CI)                                                                        1.00                 2.09 (0.75--5.96)   4.18 (1.07--21.00)   1.77 (0.57--5.54)  0.592   0.155
  **Lymph-node metastases**                                                                                                                                                                  
  No (N0)[f](#t4-fn7){ref-type="fn"}                                                              36 (76.6)                  20 (71.4)           10 (71.4)            15 (57.7)               
  Yes (N1a or N1b)[f](#t4-fn7){ref-type="fn"}                                                     11 (23.4)                  8 (28.6)             4 (28.6)            11 (42.3)               
  OR~Yes\ *vs*\ No~ (95% CI)                                                                        1.00                 0.79 (0.23--2.48)   0.80 (0.18--3.17)    1.15 (0.33--3.78)  0.938   0.853
  **Combined invasiveness**[g](#t4-fn8){ref-type="fn"}                                                                                                                                       
  None                                                                                            26 (55.3)                  7 (25.0)             2 (14.3)            7 (26.9)                
  At least one                                                                                    21 (44.7)                  21 (75.0)           12 (85.7)            19 (73.1)               
  OR~Yes\ *vs*\ No~ (95% CI)                                                                        1.00                 2.55 (0.88--7.91)   4.83 (1.08--34.33)   1.74 (0.54--5.81)  0.312   0.063
  **Multifocality**                                                                                                                                                                          
  No                                                                                              41 (87.2)                  25 (89.3)           11 (78.6)            24 (92.3)               
  Yes (*T*~m~)[f](#t4-fn7){ref-type="fn"}                                                         6 (12.8)                   3 (10.7)             3 (21.4)             2 (7.7)                
  OR~Yes\ *vs*\ No~ (95% CI)                                                                        1.00                 0.91 (0.17--4.09)   2.09 (0.36--10.46)   0.67 (0.08--3.79)  0.557   0.740
  **Benign concomitant thyroid pathology**                                                                                                                                                   
  No                                                                                              29 (61.7)                  19 (67.9)           12 (85.7)            20 (76.9)               
  Yes                                                                                             18 (38.3)                  9 (32.1)             2 (14.3)            6 (23.1)                
  OR~Yes\ *vs*\ No~ (95% CI)                                                                        1.00                 1.16 (0.39--3.41)   0.42 (0.06--1.91)    0.92 (0.26--3.13)  0.975   0.278

Abbreviations: CI=confidence interval; PTC=papillary thyroid carcinoma.

Diagnosed in the Ukrainian-American cohort study of thyroid cancer and other thyroid diseases through 2008.

*P*-value of linear (on log scale) trend or heterogeneity of trends with ^131^I dose adjusted for age at surgery.

*P-*value of linear-quadratic (on log scale) trend or heterogeneity of trends with ^131^I dose adjusted for age at surgery.

Odds ratio (OR) with ^131^I dose adjusted for age at surgery.

95% confidence interval.

Grouping according to tumour-node-metastasis classification.

At least one of the following: extrathyroidal extension, lymphatic/vascular invasion, lymph-node metastases, or distant lung metastases.

###### Associations between point mutations or chromosomal rearrangements and histopathological characteristics of 65 PTCs[a](#t5-fn2){ref-type="fn"}

                                                          **BRAF**^−^ **and RAS**^**−**^   **BRAF**^**+**^ **or RAS**^**+**^                          **Chromosomal rearrangement**^**−**^   **Chromosomal rearrangement**^**+**^                            
  ------------------------------------------------------ -------------------------------- ----------------------------------- ------- -------------- -------------------------------------- -------------------------------------- ------- ------------- -------
  **Tumour size, mm**                                                                                                                                                                                                                                    
  1--10                                                             42 (82.4)                          11 (78.6)               1.00                                22 (73.3)                              28 (87.5)                 1.00                     
  11--50                                                             9 (17.7)                          3 (21.4)                5.98    0.42--116.52                 8 (26.7)                               4 (12.5)                 0.26    0.04--1.29    0.088
  *P*[e](#t5-fn6){ref-type="fn"}                                                                                               0.186                                                                                                0.101                    
  **Presence of capsule**                                                                                                                                                                                                                                
  No                                                                44 (86.3)                          9 (64.3)                1.00                                22 (73.3)                              29 (90.6)                 1.00                     
  Yes                                                                7 (13.7)                          5 (35.7)                6.82    0.57--154.42                 8 (26.7)                               3 (9.4)                  0.32    0.04--1.96    0.063
  *P*                                                                                                                          0.132                                                                                                0.219                    
  **Dominant pattern**                                                                                                                                                                                                                                   
  Papillary                                                         17 (33.3)                          7 (50.0)                1.19    0.13--10.42                 11 (36.7)                              12 (37.5)                 2.44    0.58--11.51      
  Follicular                                                        25 (49.0)                          4 (28.6)                1.00                                15 (50.0)                              14 (43.8)                 1.00                     
  Solid                                                              9 (17.7)                          3 (21.4)                0.37     0.01--6.52                  4 (13.3)                               6 (18.8)                 2.74    0.37--23.76   0.858
  *P*                                                                                                                          0.736                                                                                                0.387                    
  **Histological variant**                                                                                                                                                                                                                               
  Papillary                                                          6 (11.8)                          5 (35.7)                7.22    0.45--184.90                 7 (23.3)                               3 (9.4)                  0.84    0.11--6.37       
  Follicular                                                        17 (33.3)                          2 (14.3)                1.00                                 9 (30.0)                              10 (31.3)                 1.00                     
  Solid                                                              5 (9.8)                           2 (14.3)                2.30    0.04--134.88                 3 (10.0)                               4 (12.5)                 0.92    0.07--12.74      
  Mixed                                                             23 (45.1)                          5 (35.7)                0.54     0.04--6.79                 11 (36.7)                              15 (46.9)                 2.86    0.64--14.82   0.221
  *P*                                                                                                                          0.266                                                                                                0.412                    
  **Intrathyroidal spreading**                                                                                                                                                                                                                           
  No                                                                 9 (17.7)                          6 (42.9)                1.00                                 8 (26.7)                               4 (12.5)                 1.00                     
  Yes                                                               42 (82.4)                          8 (57.1)                0.14     0.01--1.50                 22 (73.3)                              28 (87.5)                 2.68    0.48--17.22   0.020
  *P*                                                                                                                          0.105                                                                                                0.261                    
  **Extrathyroidal extension**                                                                                                                                                                                                                           
  No (T1 or T2)[f](#t5-fn7){ref-type="fn"}                          27 (52.9)                          12 (85.7)               1.00                                18 (60.0)                              17 (53.1)                 1.00                     
  Yes (T3)[f](#t5-fn7){ref-type="fn"}                               24 (47.1)                          2 (14.3)                0.33     0.03--2.58                 12 (40.0)                              15 (46.9)                 1.37    0.36--5.33    0.172
  *P*                                                                                                                          0.288                                                                                                0.643                    
  **Lymphatic/vascular invasion**                                                                                                                                                                                                                        
  No                                                                16 (31.4)                          9 (64.3)                1.00                                15 (50.0)                               9 (28.1)                 1.00                     
  Yes                                                               35 (68.6)                          5 (35.7)                0.14     0.01--0.95                 15 (50.0)                              23 (71.9)                 5.85    1.43--31.75   0.008
  *P*                                                                                                                          0.044                                                                                                0.013                    
  **Lymph-node metastases**                                                                                                                                                                                                                              
  No (N0)[f](#t5-fn7){ref-type="fn"}                                33 (64.7)                          11 (78.6)               1.00                                21 (70.0)                              20 (62.5)                 1.00                     
  Yes (N1a or N1b)[f](#t5-fn7){ref-type="fn"}                       18 (35.3)                          3 (21.4)                0.66     0.07--5.33                  9 (30.0)                              12 (37.5)                 1.33    0.38--4.78    0.486
  *P*                                                                                                                          0.694                                                                                                0.654                    
  **Combined invasiveness**[g](#t5-fn8){ref-type="fn"}                                                                                                                                                                                                   
  None                                                               9 (17.7)                          7 (50.0)                1.00                                 9 (30.0)                               6 (18.8)                 1.00                     
  At least one                                                      42 (82.3)                          7 (50.0)                0.23     0.02--1.86                 21 (70.0)                              26 (81.3)                 2.08    0.47--10.36   0.087
  *P*                                                                                                                          0.165                                                                                                0.336                    
  **Multifocality**                                                                                                                                                                                                                                      
  No                                                                44 (86.3)                          11 (78.6)               1.00                                28 (93.3)                              25 (78.1)                 1.00                     
  Yes (*T*~m~)[f](#t5-fn7){ref-type="fn"}                            7 (13.7)                          3 (11.4)                4.12    0.39--52.06                  2 (6.7)                                7 (21.9)                 4.32    0.64--42.85   0.799
  *P*                                                                                                                          0.237                                                                                                0.139                    
  **Benign concomitant thyroid pathology**                                                                                                                                                                                                               
  No                                                                42 (82.4)                          12 (85.7)               1.00                                26 (86.7)                              27 (84.4)                 1.00                     
  Yes                                                                9 (17.7)                          2 (14.3)                0.26     0.02--2.61                  4 (13.3)                               5 (15.6)                 3.74    0.55--31.03   0.094
  *P*                                                                                                                          0.266                                                                                                0.179                    

Abbreviations: CI=confidence interval; PTC=papillary thyroid carcinoma.

Diagnosed in the Ukrainian-American cohort study of thyroid cancer and other thyroid diseases through 2008.

Odds ratio (OR) adjusted for sex, age at surgery, oblast of residence, and ^131^I dose.

95% confidence interval.

*P*-value of heterogeneity of adjusted ORs for chromosome rearrangement-positive PTCs relative to *BRAF*/*RAS*-positive PTCs.

*P*-value of heterogeneity of adjusted ORs for chromosome rearrangement-positive PTCs relative to chromosome rearrangement-negative PTCs or *BRAF*/*RAS-*positive PTCs relative to *BRAF*/*RAS-*negative PTCs.

Grouping according to tumour-node-metastasis classification.

At least one of the following: extrathyroidal extension, lymphatic/vascular invasion, lymph-node metastases, or distant lung metastases.
